Trial reportJCO oncology practice2025
Impact of an Electronic Patient-Reported Outcome-Informed Clinical Decision Support Tool on Clinical Discussions With Head and Neck Cancer Survivors: Findings From the HN-STAR Randomized Controlled Trial (WF-1805CD).
Trial report in JCO oncology practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
purposePost-treatment head and neck cancer (HNC) survivors experience multiple symptoms and behavioral health issues. We developed Head and Neck Survivorship Tool: Assessments and Recommendation (HN-STAR), a clinical decision support tool using electronic patient-reported outcomes (ePROs) to improve follow-up of HNC survivors.
methodsWe conducted a cluster-randomized controlled trial of oncology practices in the Wake Forest National Cancer Institute Community Oncology Research Program Research Base comparing HN-STAR to usual care (UC) during a routine clinic visit. Eligible survivors completed treatment for HNC < 2 years before. Before the visit, survivors completed ePROs rating the burden of 26 concerns (symptoms and health behaviors). During the visit, HN-STAR presented survivor's concerns and tailored clinician recommendations. After the visit, survivors reported which concerns were discussed. To evaluate differences in concerns discussed in clinic, concerns were characterized as absent or mild versus burdensome, with comparisons between arms for number of concerns discussed, number of burdensome concerns discussed, and proportion of burdensome concerns discussed, assessed by mixed models adjusted for within-practice correlation.
resultsThree hundred forty-nine survivors at 28 practices reported a previsit mean of 7.5 burdensome concerns (standard deviation, 4.6), most commonly xerostomia (70%), taste changes (53%), and neck or shoulder stiffness (48%). In adjusted models, survivors in the HN-STAR arm had more burdensome concerns discussed (4.1
conclusionIn a large, national, diverse, and symptomatic sample of HNC survivors at community oncology practices, using an ePRO-informed clinical decision support tool increased the likelihood that burdensome concerns were discussed in clinic. Alerting providers to burdensome concerns and presenting guideline-concordant management options at the point of care may improve provider-survivor interactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.